QuidelOrtho Reports First Quarter 2025 Financial Results
― Total revenue of
― Strong execution on cost-savings initiatives driving improved margins and profitability ―
― Company maintains full-year 2025 financial guidance ―
First Quarter 2025 Results
(all comparisons are to the prior year period)
-
Total revenue was
$693 million -
Non-respiratory revenue was
$573 million 2% in constant currency-
Labs revenue grew
5% as reported and7% in constant currency -
Donor Screening revenue declined by
62% as the Company continues to wind down theU.S. portion of that business
-
Labs revenue grew
-
Respiratory revenue was
$120 million 11% as reported and in constant currency
-
Non-respiratory revenue was
-
GAAP operating expenses1 of
$240 million $24 million 9% ; non-GAAP operating expenses of$233 million $18 million 7% , both driven by the Company’s cost-saving initiatives -
GAAP operating margin increased from (
247% ) to5% ; adjusted EBITDA margin was23% , an increase of 450 basis points
“We delivered solid first quarter performance driven by growth in our Labs business and the strength of our recurring revenue business model,” said Brian J. Blaser, President and Chief Executive Officer, QuidelOrtho. “Our ongoing operational improvement initiatives contributed meaningfully to our results. We are proactively addressing macroenvironment operating challenges and maintaining our full-year 2025 financial guidance based on our current business outlook. As we look ahead, we remain committed to commercial excellence, margin expansion, and supporting our customers and the patients who rely on our products.”
First Quarter 2025
The Company reported total revenue for the first quarter of 2025 of
GAAP diluted loss per share for the first quarter of 2025 was
Adjusted diluted earnings per share (“EPS”) for the first quarter of 2025 was
1 Operating expenses is comprised of Selling, marketing and administrative and Research and development expenses. |
Full-year 2025 Financial Guidance
Based on its current business outlook, the Company is maintaining its fiscal 2025 financial guidance provided on February 12, 2025, as follows:
Total revenues (reported) |
|
Adjusted EBITDA |
|
Adjusted EBITDA margin |
|
Adjusted diluted EPS |
|
* Full-year 2025 total reported revenue is expected to be negatively impacted by foreign currency exchange of |
A reconciliation of forward-looking non-GAAP measures, including adjusted EBITDA, adjusted EBITDA margin and adjusted diluted EPS, to the most directly comparable GAAP measures is not provided because comparable GAAP measures for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. We are not, without unreasonable effort, able to reliably predict the impact of impairment charges and related tax benefits, employee compensation costs and other adjustments. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results. In addition, the Company believes any such reconciliation would imply a degree of precision and certainty that could be confusing to investors. See “Forward-Looking Statements” and “Non-GAAP Financial Measures.”
Conference Call Information
QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call on the “Events & Presentations” section of the “Investor Relations” page of the Company’s website at https://ir.quidelortho.com. Presentation materials will also be posted to the “Events & Presentations” section of the Investor Relations page of the Company’s website at the time of the call. Those unable to access the webcast may join the call via phone by dialing 833-470-1428 (domestic) or +1 929-526-1599 (international) and entering Conference ID number 170283.
A replay of the conference call will be available shortly after the event on the “Investor Relations” page of the Company’s website under the “Events & Presentations” section.
QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in-vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.
Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic. So that patients, clinicians and health officials can spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence.
Building upon its many years of groundbreaking innovation, QuidelOrtho continues to partner with customers across the healthcare continuum and around the globe to forge a new diagnostic frontier. One where insights and solutions know no bounds, expertise seamlessly connects and a more informed path is illuminated for each of us.
Source: QuidelOrtho Corporation
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are any statement contained herein that is not strictly historical, including, but not limited to, QuidelOrtho’s commercial, integration and other strategic goals, financial guidance and related assumptions and other future financial condition and operating results, including expected results of operations or financial position, cost-savings and operational improvement initiatives, and other future plans, objectives, strategies, expectations and intentions. Without limiting the foregoing, the words “may,” “will,” “could,” “would,” “should,” “might,” “expect,” “anticipate,” “believe,” “estimate,” “plan,” “intend,” “goal,” “project,” “strategy,” “future,” “continue,” “aim,” “strive,” “seek,” or similar words, expressions or the negative of such terms or other comparable terminology are intended to identify forward-looking statements. Such statements are based on the beliefs and expectations of QuidelOrtho’s management as of the date of this press release and are subject to significant known and unknown risks and uncertainties. Actual results or outcomes may differ significantly from those set forth or implied in the forward-looking statements. The following factors, among others, could cause actual results or outcomes to differ from those set forth or implied in the forward-looking statements: fluctuations in demand for QuidelOrtho’s non-respiratory and respiratory products; supply chain, production, logistics, distribution and labor disruptions and challenges; the challenges and costs of integrating, restructuring and achieving anticipated synergies as a result of the business combination of Quidel Corporation and Ortho Clinical Diagnostics Holdings plc; and other macroeconomic, geopolitical, market, business, competitive and/or regulatory factors affecting the business of QuidelOrtho generally, including those arising from the effects of announced or future or amended tariffs, trade policies and global trade relations, as well as others discussed in QuidelOrtho’s Annual Report on Form 10-K for the fiscal year ended December 29, 2024 and subsequent reports filed with the Securities and Exchange Commission (the “Commission”), including under Part I, Item 1A, “Risk Factors” of the Form 10-K. You should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. All forward-looking statements are based on information currently available to QuidelOrtho and speak only as of the date of this press release. QuidelOrtho undertakes no obligation to update any of the forward-looking information or time-sensitive information included in this press release, whether as a result of new information, future events, changed expectations or otherwise, except as required by law.
Non-GAAP Financial Measures
This press release contains financial measures that are considered non-GAAP financial measures under applicable rules and regulations of the Commission, including but not limited to “constant currency revenue changes, excluding COVID-19 and Donor Screening revenues,” “constant currency Labs revenue changes,” “constant currency respiratory revenue changes, excluding COVID-19 revenue,” “non-GAAP operating expenses,” “adjusted diluted EPS,” “adjusted EBITDA,” “adjusted EBITDA margin,” and other non-GAAP financial measures included in the reconciliation tables accompanying this press release. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with
QuidelOrtho |
||||||||
Consolidated Statements of Operations |
||||||||
(Unaudited) |
||||||||
(In millions except per share data) |
||||||||
|
Three Months Ended |
|||||||
|
March 30, 2025 |
|
March 31, 2024 |
|||||
Total revenues |
$ |
692.8 |
|
|
$ |
711.0 |
|
|
Cost of sales, excluding amortization of intangibles |
|
349.5 |
|
|
|
378.9 |
|
|
Selling, marketing and administrative |
|
187.0 |
|
|
|
204.7 |
|
|
Research and development |
|
53.2 |
|
|
|
59.2 |
|
|
Amortization of intangible assets |
|
48.0 |
|
|
|
51.7 |
|
|
Integration related costs |
|
16.1 |
|
|
|
22.6 |
|
|
Goodwill impairment charge |
|
— |
|
|
|
1,743.9 |
|
|
Other operating expenses |
|
6.4 |
|
|
|
8.0 |
|
|
Operating income (loss) |
|
32.6 |
|
|
|
(1,758.0 |
) |
|
Interest expense, net |
|
40.0 |
|
|
|
39.0 |
|
|
Other expense, net |
|
1.4 |
|
|
|
1.9 |
|
|
Loss before income taxes |
|
(8.8 |
) |
|
|
(1,798.9 |
) |
|
Provision for (benefit from) income taxes |
|
3.9 |
|
|
|
(92.9 |
) |
|
Net loss |
$ |
(12.7 |
) |
|
$ |
(1,706.0 |
) |
|
Basic loss per share |
$ |
(0.19 |
) |
|
$ |
(25.50 |
) |
|
Diluted loss per share |
$ |
(0.19 |
) |
|
$ |
(25.50 |
) |
|
Weighted-average shares outstanding - basic |
|
67.5 |
|
|
|
66.9 |
|
|
Weighted-average shares outstanding - diluted |
|
67.5 |
|
|
|
66.9 |
|
|
QuidelOrtho |
||||||
Condensed Consolidated Balance Sheets |
||||||
(Unaudited) |
||||||
(In millions) |
||||||
|
March 30, 2025 |
|
December 29, 2024 |
|||
ASSETS |
|
|
|
|||
Current assets: |
|
|
|
|||
Cash and cash equivalents |
$ |
127.1 |
|
$ |
98.3 |
|
Accounts receivable, net |
|
286.0 |
|
|
282.4 |
|
Inventories |
|
563.2 |
|
|
533.7 |
|
Prepaid expenses and other current assets |
|
239.8 |
|
|
262.4 |
|
Assets held for sale |
|
42.1 |
|
|
42.1 |
|
Total current assets |
|
1,258.2 |
|
|
1,218.9 |
|
Property, plant and equipment, net |
|
1,399.4 |
|
|
1,380.2 |
|
Right-of-use assets |
|
165.0 |
|
|
168.7 |
|
Goodwill |
|
670.9 |
|
|
649.5 |
|
Intangible assets, net |
|
2,697.9 |
|
|
2,735.6 |
|
Other assets |
|
270.2 |
|
|
270.7 |
|
Total assets |
$ |
6,461.6 |
|
$ |
6,423.6 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|||
Current liabilities: |
|
|
|
|||
Accounts payable |
$ |
230.9 |
|
$ |
246.0 |
|
Accrued payroll and related expenses |
|
135.3 |
|
|
116.9 |
|
Income tax payable |
|
5.8 |
|
|
5.4 |
|
Current portion of borrowings |
|
393.8 |
|
|
341.8 |
|
Other current liabilities |
|
281.4 |
|
|
288.7 |
|
Total current liabilities |
|
1,047.2 |
|
|
998.8 |
|
Operating lease liabilities |
|
163.3 |
|
|
167.2 |
|
Long-term borrowings |
|
2,105.9 |
|
|
2,141.3 |
|
Deferred tax liabilities |
|
78.2 |
|
|
76.5 |
|
Other liabilities |
|
69.8 |
|
|
55.3 |
|
Total liabilities |
|
3,464.4 |
|
|
3,439.1 |
|
Total stockholders’ equity |
|
2,997.2 |
|
|
2,984.5 |
|
Total liabilities and stockholders’ equity |
$ |
6,461.6 |
|
$ |
6,423.6 |
|
QuidelOrtho |
||||||||
Condensed Consolidated Statements of Cash Flows |
||||||||
(Unaudited) |
||||||||
(In millions) |
||||||||
|
Three Months Ended |
|||||||
|
March 30, 2025 |
|
March 31, 2024 |
|||||
Cash provided by (used for) operating activities |
$ |
65.6 |
|
|
$ |
(0.7 |
) |
|
Cash used for investing activities |
|
(56.2 |
) |
|
|
(20.2 |
) |
|
Cash provided by (used for) financing activities |
|
17.6 |
|
|
|
(18.5 |
) |
|
Effect of exchange rates on cash |
|
1.7 |
|
|
|
(1.1 |
) |
|
Net increase (decrease) in cash, cash equivalents and restricted cash |
|
28.7 |
|
|
|
(40.5 |
) |
|
Cash, cash equivalents and restricted cash at beginning of period |
|
98.5 |
|
|
|
119.5 |
|
|
Cash, cash equivalents and restricted cash at end of period |
$ |
127.2 |
|
|
$ |
79.0 |
|
|
|
|
|
|
|||||
Reconciliation to amounts within the consolidated balance sheets: |
|
|
|
|||||
Cash and cash equivalents |
$ |
127.1 |
|
|
$ |
78.5 |
|
|
Restricted cash in Other assets |
|
0.1 |
|
|
|
0.5 |
|
|
Cash, cash equivalents and restricted cash |
$ |
127.2 |
|
|
$ |
79.0 |
|
|
QuidelOrtho |
||||||||||||||||
Reconciliation of Non-GAAP Financial Information - Adjusted Net Income |
||||||||||||||||
(In millions, except per share data; unaudited) |
||||||||||||||||
|
Three Months Ended |
|||||||||||||||
|
March 30, 2025 |
|
Diluted EPS |
|
March 31, 2024 |
|
Diluted EPS |
|||||||||
Net loss |
$ |
(12.7 |
) |
|
$ |
(0.19 |
) |
|
$ |
(1,706.0 |
) |
|
$ |
(25.50 |
) |
|
Adjustments: |
|
|
|
|
|
|
|
|||||||||
Amortization of intangibles |
|
48.0 |
|
|
|
|
|
51.7 |
|
|
|
|||||
Integration related costs |
|
16.1 |
|
|
|
|
|
22.6 |
|
|
|
|||||
Goodwill impairment charge |
|
— |
|
|
|
|
|
1,743.9 |
|
|
|
|||||
Incremental depreciation on PP&E fair value adjustment |
|
5.2 |
|
|
|
|
|
9.1 |
|
|
|
|||||
Amortization of deferred cloud computing implementation costs |
|
4.3 |
|
|
|
|
|
2.9 |
|
|
|
|||||
EU medical device regulation transition costs |
|
0.2 |
|
|
|
|
|
0.6 |
|
|
|
|||||
Employee compensation charges |
|
— |
|
|
|
|
|
5.6 |
|
|
|
|||||
Other adjustments |
|
0.9 |
|
|
|
|
|
1.4 |
|
|
|
|||||
Income tax impact of adjustments |
|
(10.2 |
) |
|
|
|
|
(101.4 |
) |
|
|
|||||
Discrete tax items |
|
(1.6 |
) |
|
|
|
|
(0.6 |
) |
|
|
|||||
Adjusted net income |
$ |
50.2 |
|
|
$ |
0.74 |
|
|
$ |
29.8 |
|
|
$ |
0.44 |
|
|
Weighted-average shares outstanding - diluted |
|
|
|
67.9 |
|
|
|
|
|
67.3 |
|
|||||
QuidelOrtho |
||||||||||||||||||
Reconciliation of Non-GAAP Financial Information - Non-GAAP Operating Expenses |
||||||||||||||||||
(In millions, unaudited) |
||||||||||||||||||
|
Three Months Ended March 30, 2025 |
|
Three Months Ended March 31, 2024 |
|||||||||||||||
|
GAAP |
|
Adjustments(a) |
|
Non-GAAP |
|
GAAP |
|
Adjustments(a) |
|
Non-GAAP |
|||||||
Selling, marketing and administrative |
$ |
187.0 |
|
$ |
(6.8) |
|
$ |
180.2 |
|
$ |
204.7 |
|
$ |
(12.3) |
|
$ |
192.4 |
|
Research and development |
|
53.2 |
|
|
(0.5) |
|
|
52.7 |
|
|
59.2 |
|
|
(0.8) |
|
|
58.4 |
|
Operating expenses |
$ |
240.2 |
|
$ |
(7.3) |
|
$ |
232.9 |
|
$ |
263.9 |
|
$ |
(13.1) |
|
$ |
250.8 |
|
(a) |
Includes the following non-GAAP adjustments: amortization of deferred cloud computing implementation costs, incremental depreciation on PP&E fair value adjustment, employee compensation charges, EU medical device regulation transition costs and other adjustments. |
|
QuidelOrtho |
||||||||
Reconciliation of Non-GAAP Financial Information - Adjusted EBITDA |
||||||||
(In millions, unaudited) |
||||||||
|
Three Months Ended |
|||||||
|
March 30, 2025 |
|
March 31, 2024 |
|||||
Net loss |
$ |
(12.7 |
) |
|
$ |
(1,706.0 |
) |
|
Depreciation and amortization |
|
107.1 |
|
|
|
114.9 |
|
|
Interest expense, net |
|
40.0 |
|
|
|
39.0 |
|
|
Provision for (benefit from) income taxes |
|
3.9 |
|
|
|
(92.9 |
) |
|
Integration related costs |
|
16.1 |
|
|
|
22.6 |
|
|
Goodwill impairment charge |
|
— |
|
|
|
1,743.9 |
|
|
Amortization of deferred cloud computing implementation costs |
|
4.3 |
|
|
|
2.9 |
|
|
EU medical device regulation transition costs |
|
0.2 |
|
|
|
0.6 |
|
|
Employee compensation charges |
|
— |
|
|
|
5.6 |
|
|
Other adjustments |
|
0.9 |
|
|
|
1.4 |
|
|
Adjusted EBITDA |
$ |
159.8 |
|
|
$ |
132.0 |
|
|
|
|
|
|
|||||
Total revenues |
$ |
692.8 |
|
|
$ |
711.0 |
|
|
Adjusted EBITDA margin |
|
23.1 |
% |
|
|
18.6 |
% |
|
QuidelOrtho |
||||||||||||||||
Reconciliation of Non-GAAP Financial Information - Revenues by Business Unit and Region |
||||||||||||||||
(In millions, unaudited) |
||||||||||||||||
|
Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|||||
|
March 30, 2025 |
|
March 31, 2024 |
|
% Change |
|
Currency Impact |
|
Constant Currency (a) |
|
Less: COVID-19 revenue impact |
|
Constant Currency (a) ex COVID-19 Revenue |
|||
Respiratory revenues |
$ |
119.8 |
|
$ |
137.3 |
|
(12.7)% |
|
(0.1)% |
|
(12.6)% |
|
(23.4)% |
|
10.8 % |
|
Non-Respiratory revenues |
|
573.0 |
|
|
573.7 |
|
(0.1)% |
|
(1.8)% |
|
1.7 % |
|
— % |
|
1.7 % |
|
Total revenues |
$ |
692.8 |
|
$ |
711.0 |
|
(2.6)% |
|
(1.5)% |
|
(1.1)% |
|
(4.0)% |
|
2.9 % |
|
|
Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|||||
|
March 30, 2025 |
|
March 31, 2024 |
|
% Change |
|
Currency Impact |
|
Constant Currency (a) |
|
Less: COVID-19 revenue impact |
|
Constant Currency (a) ex COVID-19 Revenue |
|||
Labs |
$ |
373.1 |
|
$ |
356.9 |
|
4.5 % |
|
(2.2)% |
|
6.7 % |
|
(0.1)% |
|
6.8 % |
|
Immunohematology |
|
128.5 |
|
|
127.0 |
|
1.2 % |
|
(2.5)% |
|
3.7 % |
|
— % |
|
3.7 % |
|
Donor Screening |
|
12.8 |
|
|
33.3 |
|
(61.6)% |
|
(0.1)% |
|
(61.5)% |
|
— % |
|
(61.5)% |
|
Point of Care |
|
170.8 |
|
|
186.6 |
|
(8.5)% |
|
(0.1)% |
|
(8.4)% |
|
(15.9)% |
|
7.5 % |
|
Molecular Diagnostics |
|
7.6 |
|
|
7.2 |
|
5.6 % |
|
(1.6)% |
|
7.2 % |
|
(3.6)% |
|
10.8 % |
|
Total revenues |
$ |
692.8 |
|
$ |
711.0 |
|
(2.6)% |
|
(1.5)% |
|
(1.1)% |
|
(4.0)% |
|
2.9 % |
|
|
Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|||||
|
March 30, 2025 |
|
March 31, 2024 |
|
% Change |
|
Currency Impact |
|
Constant Currency (a) |
|
Less: COVID-19 revenue impact |
|
Constant Currency (a) ex COVID-19 Revenue |
|||
|
$ |
406.7 |
|
$ |
433.9 |
|
(6.3)% |
|
0.2 % |
|
(6.5)% |
|
(5.9)% |
|
(0.6)% |
|
EMEA |
|
88.9 |
|
|
84.8 |
|
4.8 % |
|
(3.8)% |
|
8.6 % |
|
(0.3)% |
|
8.9 % |
|
|
|
75.0 |
|
|
76.1 |
|
(1.4)% |
|
(1.3)% |
|
(0.1)% |
|
— % |
|
(0.1)% |
|
Other |
|
122.2 |
|
|
116.2 |
|
5.2 % |
|
(7.1)% |
|
12.3 % |
|
(0.7)% |
|
13.0 % |
|
Total revenues |
$ |
692.8 |
|
$ |
711.0 |
|
(2.6)% |
|
(1.5)% |
|
(1.1)% |
|
(4.0)% |
|
2.9 % |
|
| (a) |
The term “constant currency” means we have translated local currency revenues for all reporting periods to |
|
QuidelOrtho |
||||||||||||||
Reconciliation of Non-GAAP Financial Information - Revenue excluding COVID-19 and Donor Screening |
||||||||||||||
(In millions, unaudited) |
||||||||||||||
|
Three Months Ended |
|
|
|
|
|
|
|||||||
|
March 30, 2025 |
|
March 31, 2024 |
|
% Change |
|
Currency Impact |
|
Constant Currency (a) |
|||||
Total revenues |
$ |
692.8 |
|
|
$ |
711.0 |
|
|
(2.6)% |
|
(1.5)% |
|
(1.1)% |
|
COVID-19 revenue |
|
(23.4 |
) |
|
|
(50.2 |
) |
|
|
|
|
|
|
|
Donor Screening revenue |
|
(12.8 |
) |
|
|
(33.3 |
) |
|
|
|
|
|
|
|
Total revenue, excluding COVID-19 and Donor Screening |
$ |
656.6 |
|
|
$ |
627.5 |
|
|
4.6 % |
|
(1.8)% |
|
6.4 % |
|
QuidelOrtho |
||||||||||||||
Reconciliation of Non-GAAP Financial Information - Respiratory Revenue excluding COVID-19 |
||||||||||||||
(In millions, unaudited) |
||||||||||||||
|
Three Months Ended |
|
|
|
|
|
|
|||||||
|
March 30, 2025 |
|
March 31, 2024 |
|
% Change |
|
Currency Impact |
|
Constant Currency (a) |
|||||
Respiratory revenues |
$ |
119.8 |
|
|
$ |
137.3 |
|
|
(12.7)% |
|
(0.1)% |
|
(12.6)% |
|
COVID-19 revenue |
|
(23.4 |
) |
|
|
(50.2 |
) |
|
|
|
|
|
|
|
Total respiratory revenue, excluding COVID-19 |
$ |
96.4 |
|
|
$ |
87.1 |
|
|
10.7 % |
|
(0.1)% |
|
10.8 % |
|
| (a) |
The term “constant currency” means we have translated local currency revenues for all reporting periods to |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250507217806/en/
Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@quidelortho.com
Media Contact:
D. Nikki Wheeler
Senior Director, Corporate Communications
media@quidelortho.com
Source: QuidelOrtho Corporation
